"I’m motivated by working with a highly talented, multi-disciplinary group of scientists extremely focused on taking on the toughest challenges in the discovery for transformational therapies."
I joined Genentech in 2012 after spending 4 years at Schering-Plough/Merck working on multiple virology programs. I received my PhD in 2008 from Stanford working with Paul Wender on natural product analog design and synthesis. During my PhD, it was extremely satisfying taking complex compounds I had synthesized myself and running biochemical and cellular assays to evaluate their activity. This training prepared me extremely well for a career in medicinal chemistry.
J. Med. Chem., 2020, 63, 14357–14381.
Nature 2018, 557, 196-201.
Nucleosides, Nucleotides and Nucleic Acids 2016, 35, 277–294.
Biorg. Med. Chem. Lett. 2012, 22, 6967-6973.
Bioorg. Med. Chem. Lett. 2012, 22, 5652-5657.
Tetrahedron Lett. 2012, 53, 3203-3205.
Bioorg. Med. Chem. Lett. 2012, 22, 3229-3234.
Tetrahedron Lett. 2010, 51, 4284-4286.
I lead teams focused on advancing novel chemical matter against tough-to-drug targets across a range of therapeutic areas including oncology, immunology and infectious disease. In this role, I have led teams taking on challenges including Genentech’s first foray into novel reversible covalent modalities that are increasingly being utilized across the industry as well as advancing hits to compounds that are active against multiple wild-type Gram-negative bacteria, including multi-drug resistant strains. I have also contributed to teams that have delivered both traditional small molecule therapeutics as well as antibody-drug conjugates into the clinic.